Darren M. Smith, MD, FACS: Plastic Surgery

Darren M. Smith, MD, FACS operates a plastic surgery practice in New York, NY, where he combines surgical expertise with medical weight management solutions including tirzepatide therapy. Dr. Smith holds board certification from the American Board of Plastic Surgery and Fellowship designation from the American College of Surgeons, credentials that reflect completion of rigorous training standards in plastic and reconstructive surgery. His practice serves Manhattan patients seeking both surgical body contouring procedures and non-surgical metabolic interventions for weight optimization.

Tirzepatide represents the practice's primary peptide offering, a dual GIP/GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight conditions accompanied by weight-related comorbidities. This medication works through two distinct pathways: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor activation, which together regulate appetite, food intake, and glucose metabolism. Patients typically receive weekly subcutaneous injections with dosing titrated over several months to minimize gastrointestinal side effects while achieving therapeutic benefit. The integration of tirzepatide into a plastic surgery practice allows Dr. Smith to address weight management both before surgical procedures—optimizing candidacy and reducing perioperative risk—and as a standalone intervention for patients pursuing non-surgical options. This dual approach reflects the evolving understanding that sustainable aesthetic outcomes often require addressing underlying metabolic factors alongside surgical technique.

Dr. Smith's academic background includes over 200 peer-reviewed publications, positioning him among the most research-active plastic surgeons practicing in New York. This publication record spans topics in aesthetic surgery, reconstructive techniques, and patient safety protocols, demonstrating sustained engagement with evidence-based practice evolution. His dual fellowship training provides specialized expertise beyond standard plastic surgery residency, though the specific fellowship focus areas inform his surgical approach to body contouring procedures that patients frequently combine with medical weight management. The practice employs nursing staff who manage tirzepatide administration protocols, patient education regarding injection technique for home use, and monitoring for adverse effects including nausea, vomiting, diarrhea, and potential pancreatitis symptoms that require clinical attention.

Patients initiating tirzepatide therapy at the practice undergo initial consultation to assess candidacy, including review of contraindications such as personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The treatment protocol involves baseline metabolic assessment, discussion of realistic weight loss expectations (clinical trials demonstrate average body weight reduction of 15-20% over 72 weeks at maximum dosing), and establishment of monitoring schedules for both efficacy and safety parameters. Follow-up visits track weight trends, tolerance of dose escalation, and any concerning symptoms. For surgical patients, the practice manager coordinates timing between weight stabilization on tirzepatide and scheduled procedures, as significant ongoing weight loss can affect surgical planning for body contouring operations. The practice's location in Manhattan provides access to patients throughout New York's five boroughs and surrounding areas who seek the combination of surgical expertise and medical weight management under unified care.

The practice differentiates itself through Dr. Smith's research background and the integration of evidence-based medical therapies into a surgical practice framework. While many plastic surgery practices refer weight management to separate providers, this model allows for coordinated care planning where metabolic optimization and surgical intervention inform each other. Patients receive tirzepatide prescriptions with clear protocols for dose escalation, dietary modification recommendations that complement GLP-1 mechanism of action, and direct access to the surgical team for questions about how weight changes affect surgical candidacy or timing. The practice does not offer telehealth-exclusive tirzepatide prescribing; patients establish care through in-person consultation in the New York office, ensuring comprehensive evaluation and integration with the practice's broader aesthetic treatment planning.